Functional Specialization of Skin Dendritic Cell Subsets in Regulating T Cell Responses by Björn E. Clausen & Patrizia Stoitzner
October 2015 | Volume 6 | Article 5341
Review
published: 22 October 2015
doi: 10.3389/fimmu.2015.00534
Frontiers in Immunology | www.frontiersin.org
Edited by: 
Stefan F. Martin, 
University of Freiburg, Germany
Reviewed by: 
Miriam Wittmann, 
University of Leeds, UK 
Susan Kovats, 
Oklahoma Medical Research 
Foundation, USA
*Correspondence:
Björn E. Clausen 
bclausen@uni-mainz.de; 
 Patrizia Stoitzner 
patrizia.stoitzner@i-med.ac.at
Specialty section: 
This article was submitted to 
Immunological Memory, 
a section of the 





Clausen BE and Stoitzner P (2015) 
Functional specialization of skin 
dendritic cell subsets in regulating 
T cell responses. 
Front. Immunol. 6:534. 
doi: 10.3389/fimmu.2015.00534
Functional specialization of skin 
dendritic cell subsets in regulating  
T cell responses
Björn E. Clausen1* and Patrizia Stoitzner2*
1 Institute for Molecular Medicine, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, 
2 Department of Dermatology and Venereology, Division of Experimental Dermatology, Medical University of Innsbruck, 
Innsbruck, Austria
Dendritic cells (DC) are a heterogeneous family of professional antigen-presenting cells 
classically recognized as most potent inducers of adaptive immune responses. In this 
respect, Langerhans cells have long been considered to be prototypic immunogenic DC 
in the skin. More recently this view has considerably changed. The generation of in vivo 
cell ablation and lineage tracing models revealed the complexity of the skin DC net-
work and, in particular, established the existence of a number of phenotypically distinct 
Langerin+ and negative DC populations in the dermis. Moreover, by now we appreciate 
that DC also exert important regulatory functions and are required for the maintenance of 
tolerance toward harmless foreign and self-antigens. This review summarizes our current 
understanding of the skin-resident DC system in the mouse and discusses emerging 
concepts on the functional specialization of the different skin DC subsets in regulating T 
cell responses. Special consideration is given to antigen cross-presentation as well as 
immune reactions toward contact sensitizers, cutaneous pathogens, and tumors. These 
studies form the basis for the manipulation of the human counterparts of the murine DC 
subsets to promote immunity or tolerance for the treatment of human disease.
Keywords: contact hypersensitivity, cross-presentation, dendritic cells, immunotherapy, infectious skin disease, 
Langerhans cells, Langerin, skin cancer
iNTRODUCTiON
The skin is the second largest barrier organ to the outside world besides the intestine. As such it is 
not only exposed to physical stress but also to a wide variety of environmental antigens, including 
chemicals, commensal bacteria, and pathogens. Hence, the skin immune system must be prepared to 
detect and discriminate between these diverse antigens and subsequently induce appropriate tolero-
genic or protective immune responses. To this aim, the skin contains a heterogeneous population 
of dendritic cells (DC, from Greek dendron “tree”) that represent key regulators of both innate and 
adaptive immune responses. While skin DC play a critical role in guarding the host against invading 
pathogens and at the same time limiting collateral tissue damage, they are also associated with the 
breakdown of peripheral tolerance leading to chronic immune-mediated inflammatory diseases 
such as allergic contact dermatitis and psoriasis. As essential mediators of cutaneous immune reac-
tions and homeostasis, considerable work has been focused to unravel the origins, phenotypic, and 
functional differences of the cells of the skin DC network (1–3).
October 2015 | Volume 6 | Article 5342
Clausen and Stoitzner Functional specialization of skin DC
Frontiers in Immunology | www.frontiersin.org
Anatomically, the skin can be divided into an outer epidermis 
and the underlying dermis, which are separated by a basement 
membrane. The cell-free basement membrane acts as a mechanical 
barrier, however, its primary function is to anchor the epithelium 
(epidermis) to the loose connective tissue (dermis) underneath. 
The epidermis represents a stratified epithelial layer composed 
of keratinocytes that generate the water-impermeable stratum 
corneum. The dermis is a cell-poor layer consisting of fibroblasts 
that produce the extracellular matrix containing proteoglycans 
and entwined collagen and elastic fibers. Together they enable 
the skin to resist stretching and tearing forces. In addition to 
forming the primary physical barrier, keratinocytes also actively 
contribute to the immunological barrier of the skin. They are 
equipped with most toll-like receptors (TLR), except TLR7 and 
TLR8 (4–6). Following TLR triggering and NOD-like receptor 
(NLR)-mediated inflammasome activation, keratinocytes secrete 
antimicrobial peptides and many proinflammatory cytokines as 
well as chemokines for the recruitment of neutrophils. Thereby 
keratinocytes participate in adaptive immune activation, via 
inducing DC mobilization and migration to skin-draining lymph 
nodes (LN), and innate immune modulation (7).
DC can be subdivided into conventional DC and plasmacy-
toid DC (pDC). Healthy skin contains no or very few pDC (8, 9); 
they only enter inflamed skin to promote wound healing through 
type-I interferons (9) or mediate the proinflammatory reaction 
that develops after TLR7 stimulation, for example, during psoria-
sis (10). An excellent overview of pDC biology and plasticity has 
recently been published elsewhere and these cells are not further 
discussed here (11).
In the steady state, the conventional DC residing in the skin 
are not inactive. Rather as immature cells, they constantly probe 
their environment for invading pathogens and continuously 
sample self- and environmental antigens (Figure  1). To this 
aim, epidermal Langerhans cells (LC) exhibit a unique behavior 
characterized by rhythmic extension and retraction of their den-
drites through intercellular spaces between keratinocytes, which 
is amplified during inflammation (12). In fact, LC can extend 
dendrites through tight junctions to survey the skin surface and 
elicit humoral immunity to antigens that have not yet violated 
the epidermal barrier, providing preemptive immunity against 
potentially pathogenic skin microbes (13).
A small fraction of LC and dermal DC undergoes spontane-
ous maturation through a mechanism that is not yet understood 
(14). This homeostatic or phenotypic maturation involves the 
upregulation of chemokine receptor CCR7, which enables DC 
migration to the skin-draining LN (15), and in the case of LC 
downregulation of E-cadherin to detach themselves from the sur-
rounding keratinocytes (16). Moreover, disruption of E-cadherin 
binding may actively promote a tolerogenic LC phenotype via 
the release and nuclear localization of β-catenin (17, 18). During 
their migration to the T cell areas of local LN, the cells upregulate 
surface expression of MHC/peptide complexes for recognition 
of and interaction with antigen-specific naïve T cells (Figure 1) 
(19–22). Upon encounter with potentially autoreactive T cells 
that have escaped central tolerance or with T cells recognizing 
peptides derived from innocuous foreign antigens, these DC 
induce T cell anergy or deletional T cell tolerance (tolerizing 
function) (23–26). In addition, the frequent T cell–DC contacts 
during T cell scanning of DC in lymphoid organs, i.e., in the 
absence of cognate antigen, induce a basal activation level in 
T cells required for rapid responsiveness to subsequent encoun-
ters with foreign antigen during inflammation (27).
Pathogen invasion together with proinflammatory signals drive 
the full functional maturation of skin DC. Beyond the homeostatic 
differentiation program, the cells now also upregulate the expres-
sion of costimulatory molecules and, in particular, proinflam-
matory cytokines. Together these promote clonal expansion of 
naïve antigen-specific T cells and instruct the T cells to acquire 
appropriate effector functions specifically tailored to eliminate the 
invading pathogen (sensitizing function) (Figure 1) (19).
In this review, we describe our current understanding of the 
composition of the skin DC network and summarize the tran-
scription and growth factor requirements for the development of 
the different skin DC populations. We then discuss the functional 
specialization of skin DC subsets in the context of allergic and 
infectious skin disease models, as well as their cross-presentation 
capacity and their role in skin cancer. Finally, we focus on how 
this knowledge may be applied to harness skin DC for therapeutic 
purposes and, to this aim, conclude with a comparison of mouse 
and human skin DC subsets.
THe SKiN-ReSiDeNT DeNDRiTiC  
CeLL NeTwORK
After the discovery of DC by Ralph Steinman and Zanvil Cohn in 
1973 (28), it was only in 1985 that epidermal LC (Figure 2), first 
described by Paul Langerhans as “Nerven der menschlichen Haut” 
more than a century before (29), were unequivocally placed into 
the DC family (30, 31). One of the most important findings of these 
early studies on LC was that DC exist in two phenotypically and 
FiGURe 1 | The Langerhans cell paradigm: Ralph Steinman’s scheme 
of key dendritic cell functions. DC, including epidermal LC, exist in two 
phenotypically and functionally distinct states: as immature cells highly 
specialized in antigen uptake and processing and as mature cells committed 
to antigen presentation that activate or tolerize naïve T cells. The two 
functional programs are connected by DC migration from peripheral tissues 
to draining LN, which is essential for naïve T cells to encounter their cognate 
antigen.
FiGURe 3 | Skin dendritic cell subsets in mice. Scanning electron microscopy picture of a skin section depicting several layers of keratinocytes and the collagen 
meshwork of the dermis (38). Photograph by courtesy of Kristian Pfaller and Patrizia Stoitzner. Phenotypically distinct murine skin-resident DC subsets are depicted, 
including the most commonly used markers for their identification. The color code matches the human counterparts shown in Figure 4.
FiGURe 2 | Langerhans cells: sentinels of the skin. (A) LC network 
visualized in an epidermal sheet of mouse ear skin with MHC-II antibody 
staining (green fluorescence) (37). Photograph by courtesy of Julia 
Ober-Blöbaum and Björn Clausen. (B) Scanning electron microscopy of a LC 
sitting on a keratinocyte (38). Photograph by courtesy of Kristian Pfaller and 
Patrizia Stoitzner.
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functionally distinct states: as immature cells that are highly phago-
cytic and specialized to take up and process antigen, and as mature 
cells dedicated to identify and stimulate rare antigen-specific naïve 
T cells in secondary lymphoid organs (Figure 1). This  observation 
is directly linked to another unique function of DC, namely, their 
migration via afferent lymphatics into the T cell areas of secondary 
lymphoid organs (19). In fact, in early mixed lymphocyte reaction 
(MLR) experiments DC turned out to be about 100-fold more 
efficient at inducing naive T cell proliferation than macrophages 
(32–34), which also do not travel from peripheral tissues to local 
LN (35). Owing to their easy accessibility and a large body of 
in  vitro work, which almost inevitably triggers LC functional 
maturation, much of what we know today about the role of DC 
as most potent inducers of T cell immune responses stems from 
studying LC biology. Hence, for a long time LC were considered 
prototypic immunogenic DC for which Wilson and Villadangos 
later coined the term “LC paradigm” (36) and dermal DC were 
largely overlooked.
This picture began to change dramatically with the identifica-
tion of Langerin (CD207), a novel C-type lectin specific to LC 
(39–41) and the generation of anti-Langerin monoclonal anti-
bodies (42, 43). Although originally described as a LC-specific 
marker, in combination with constitutive and inducible Langerin+ 
cell depletion models and a Langerin-EGFP knock-in allele 
(44–46), this led to the discovery of a small Langerin+ dermal 
DC subset that is ontogenetically and phenotypically distinct 
of epidermal LC (47–49). Largely owing to the comprehensive 
analysis of the Malissen lab to disentangle the complexity of the 
skin DC network, we can currently distinguish five distinct DC 
subsets in healthy mouse skin (Figure 3) (50, 51). All of these DC 
populations express CD11c and MHC class II (MHC-II). (i) LC in 
the epidermis as well as in the dermis – en route to skin-draining 
LN – can be identified as Langerin+CD11b+EpCam+Sirpα+ cells, 
and distinguished from CD11b+Sirpα+ dermal DC by their 
absence of Langerin and EpCam staining. (ii) CD11b+ DC are 
the most abundant subset and comprise about 65% of all dermal 
DC (51). (iii and iv) Langerin+CD11bneg dermal DC, on the 
other hand, are unambiguously recognized by expression of the 
chemokine receptor XCR1, lack EpCam and Sirp1α, and can be 
further divided into a CD103+ and negative subset. Expression 
of XCR1 is shared by all CD11bneg non-lymphoid and CD8α+ 
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lymphoid tissue DC, respectively, but only XCR1+CD11bneg DC in 
the dermis co-express Langerin (52, 53). Of note, in the skin sur-
face expression of CD24 correlates with that of Langerin and can 
be used for the purification of viable LC and Langerin+ dermal DC 
by flow cytometry. (v) Finally, the dermis harbors a minor popu-
lation of LangerinnegXCR1neg double-negative DC that express 
low levels of CD11b and Sirpα, and are uniquely CX3CR1high (51). 
These five conventional skin DC populations can be separated 
from dermal macrophages and monocyte-derived DC by the use 
of CD64 (35). In particular during inflammation, large numbers 
of monocytes infiltrate the skin where they differentiate into 
CD11b+Ly6C+CD64+ monocyte-derived DC that have very low 
or lack CD11c expression. These recently identified cells play a 
role mainly in activating skin-resident T cells and disappear after 
resolution of the inflammation (35). The functional specialization 
of LC and the different dermal DC populations that are present in 
mouse skin will be discussed below.
ORiGiN, TRANSCRiPTiON FACTOR, AND 
SURvivAL FACTOR ReQUiReMeNTS OF 
SKiN DeNDRiTiC CeLL POPULATiONS
LC are radio-resistant cells that reside in the supra-basal layer of 
the epidermis, closely attached to the surrounding keratinocytes 
via E-cadherin containing adherens junctions. In the steady 
state, LC exhibit a low rate of proliferation that – unlike dermal 
DC – is sufficient to maintain the cells locally throughout life as 
has been demonstrated by parabiosis experiments in mice (54) 
and could also be observed in human skin of hand transplant 
patients (55). Only in response to inflammatory changes lead-
ing to an increased loss from the epidermis are LC replaced 
by blood-borne progenitors. These precursors were recruited 
in a CCR2-dependent way and identified to represent Ly6Chigh 
monocytes that enter inflamed skin and differentiate into LC in 
the epidermis (56, 57). Whether these monocyte-derived LC are 
functionally similar and equally capable to maintain themselves 
in situ remains elusive. Recent experiments indicate that the initial 
wave of monocyte-derived LC reconstitution after UV radiation 
and contact sensitizer exposure generates only short-term LC 
that are transient and replaced by a second wave of steady-state 
precursor-derived long-term LC (58, 59). On the other hand, all 
dermal DC populations in healthy skin are radiosensitive, have a 
short lifespan, and are continuously replaced by a circulating pool 
of bone marrow-derived DC precursors (60).
In contrast to dermal DC that originate from DC-restricted 
progenitors [reviewed in Ref. (2, 60)], during ontogeny LC arise 
first from yolk sac-derived primitive myeloid precursors around 
embryonic day 18 that are largely replaced by fetal liver-derived 
monocytes during late embryogenesis (61). These LC precursors 
then acquire a DC morphology and phenotype, including CD11c 
and MHC-II expression immediately after birth (62), whereas 
Langerin expression becomes apparent only 2–3 days after birth 
and reaches adult levels of intensity only by 3 weeks of age (63). 
Moreover, between postnatal days 2 and 7 the LC undergo a 
massive proliferative burst (62), before reaching a typical density 
of about 700–1,000  LC/mm2 in the epidermis of adult mice 
(37) (Figure 2). Intriguingly, LC share this embryonic ancestry 
from myeloid precursors and the capacity of self-maintenance 
throughout life without any input from the bone marrow with 
brain microglia. While macrophage colony-stimulating factor 1 
(M-CSF or CSF-1) is essential for the development of most tissue 
macrophages and partly for CD11b+ dermal DC (64), CSF-1R-
deficient mice in addition lack both LC and microglia. Their 
development requires the presence of the alternative CSF-1R 
ligand IL-34 that is constitutively produced by keratinocytes and 
neurons (65, 66). Based on this unique life cycle and the shared 
pedigree with certain tissue macrophages, LC have recently been 
grouped into the same lineage as macrophages (67, 68). Although 
ontogenetically LC and macrophages are closely related cells, in 
stark contrast to the sessile tissue macrophages LC migrate to LN 
where they prime naïve T cells to induce regulatory or effector 
responses. Since migration and naïve T cell priming represent 
cardinal features characterizing conventional DC (Figure  1), 
we strongly favor to keep LC in the DC family. Reciprocally, 
from a semantic point of view it has to be stressed that the term 
“macrophage” (from Greek makrós “large, big” and phagein 
“eat” = “big eaters”) describes a function for which DC are cer-
tainly not specialized as has been worked out so beautifully by 
Ralph Steinman (69–71).
Another cytokine that has been known for a long time to be 
essential for LC differentiation is transforming growth factor-β1 
(TGF-β1) (72). Although TGF-β1 is produced by both LC and 
keratinocytes, LC promote their own development through an 
autocrine loop of TGF-β1 secretion and signaling (73). In addi-
tion, TGF-β1 is required to maintain the network of immature LC 
in the epidermis (74, 75). In line with the critical role of TGF-β1 
for LC development, mice lacking the TGF-β1-induced transcrip-
tion factor inhibitor of DNA binding 2 (Id2), or the transcrip-
tion factor Runx3 that mediates DC responses to TGF-β1 both 
also lack LC (76–78). Moreover, Id2−/− mice have dramatically 
reduced numbers of lymphoid organ CD8+ and non-lymphoid 
tissue CD103+ DC (64).
The cytokine Flt3L is a key mediator of DC commitment 
during hematopoiesis (79) and injection of Flt3L into mice dra-
matically increased DC numbers in various tissues (80). Beyond 
its role in DC differentiation, Flt3L regulates the homeostatic 
proliferation of DC to maintain peripheral DC numbers in the 
steady state (81). With respect to skin DC subsets, LC are not 
affected by the absence of Flt3 or its ligand, whereas dermal DC 
were reduced in Flt3−/− and Flt3L−/− mice (64, 82). Granulocyte/
macrophage colony-stimulating factor (GM-CSF or CSF-2) is 
essential for DC differentiation (83), and mice lacking either 
CSF-2 or its receptor display a reduction of LC and CD103+ 
dermal DC (84, 85). In the absence of macrophage colony-
stimulating factor (M-CSF or CSF-1), LC numbers were halved 
(86), and mice that lack the M-CSF receptor (CSF-1R) have no 
LC and reduced CD11b+ dermal DC, while CD103+ dermal DC 
develop normally (56, 64).
Moreover, a number of interferon regulatory factors (IRF) 
and other transcription factors have been implicated in the 
development of different DC subsets, albeit with incomplete 
available information concerning their effects on LC and 
dermal DC. IRF2-deficient mice exhibit reduced numbers of 
TABLe 1 | Phenotypes of transcription factor and growth factor/receptor knockout mice lacking specific skin-resident dendritic cell subsetsa.
Transcription/growth factor/
receptor knockout
Lymphoid tissue DC Skin/non-lymphoid tissue DC Reference
CD8+ DC CD8neg DC LC CD103+ DC CD11b+ DC
Batf3 – ↔ ↔ – ↔ (91, 92, 98)
CSF-1 (M-CSF) ↔ ↔ ↓ n.d. n.d. (86)
Csf-1R ↔ ↔ – ↔ ↓ (56, 64–66)
CSF-2 (GM-CSF) ↔ ↔ ↓ ↓ ↔ (83–85)
Csf-2R ↔ ↔ ↔ ↓ ↔ (84, 85)
IL-34 ↔ ↔ – ↔ ↔ (65, 66)
Flt3 ↓ ↓ ↔ ↓ ↓ (64, 79, 81, 82)
Id2 – ↔ – – ↔ (64, 76, 78)
IRF2 ↑ ↓ ↓ n.d. n.d. (87)
IRF4 ↑ ↓ ↔ ↑ ↑ (76, 88–90, 93)
IRF8 – ↔ ↔ – ↔ (64, 76, 91–93, 98)
LAMTOR ↔ ↔ – ↓ n.d. (59)
Runx3 ↑ ↓ – n.d. n.d. (77)
TGF-β1 ↔ ↔ – ↔ ↔ (72–75)
Zbtb46b ↔ ↔ ↓ ↓ ↓ (82, 99, 100)
a– indicates an absent cell population, ↓ indicates a reduction, ↔ no change, and ↑ an increase in cell number.
bIncludes data from diphtheria toxin-treated Zbtb46-DTR bone marrow chimeras.
n.d. = not determined.
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splenic CD4+ DC and epidermal LC, while dermal DC subsets 
have not been assessed (87); IRF4−/− mice harbor reduced 
numbers of splenic CD4+ DC and of migratory LN DC due to a 
defect in dermal DC migration, which leads to an accumulation 
of CD103+ and CD11b+ dermal DC in the skin (88–90); and 
IRF8−/− mice lack splenic CD8+ DC and non-lymphoid tissue 
CD103+ DC, including CD103+ dermal DC, whereas LC are 
unaffected (64, 76, 91–93). In addition, IRF8 also contributes 
to DC function: IRF8 controls CD8+ DC maturation and IL-12 
production (94), antigen uptake and MHC-II presentation 
(95), the migration of LC and dermal DC to local LN (96), 
and the tolerogenic function of DC by inducing the expression 
of indoleamine 2,3-dioxygenase (IDO) (97). Although the 
basic leucine zipper transcription factor ATF-like 3 (Batf3) 
is expressed in all conventional DC, including CD11b+ DC, 
Batf3−/− mice reveal a selective deficiency of CD8+ and CD103+ 
DC, however, the penetrance of the CD8+ DC defect seems to 
depend on the inbred background (91, 98). The transcription 
factor Zbtb46 represents a negative regulator of DC activation 
and Zbtb46-deficient mice display no alterations in DC numbers 
(99, 100). Nevertheless, in Zbtb46-DTR bone marrow chimeras 
LC and all dermal DC subsets are depleted by the injection 
of diphtheria toxin (82). The deletion of the late endosomal 
adaptor molecule p14 (LAMTOR2) caused a gradual loss of LC 
from newborn mice due to increased apoptosis and a defect 
in homeostatic LC proliferation. This effect is partly mediated 
by the downregulation of TGF-β receptor II on LC (59, 101). 
The phenotypes of different cytokine-, growth factor-, and 
transcription factor-deficient mice lacking distinct DC subsets 
are summarized in Table 1.
In conclusion, the various skin DC subsets vary in their 
dependency on different transcription and growth factors, which 
allows the manipulation of particular subsets to investigate their 
functional properties. Our current knowledge on the specific roles 
of cutaneous DC subsets in allergic and infectious skin diseases as 
well as in skin cancer will be discussed in the following sections.
FUNCTiONAL ReDUNDANCY OF SKiN 
DeNDRiTiC CeLLS iN CONTACT 
HYPeRSeNSiTiviTY
Contact hypersensitivity (CHS) responses to topically applied 
haptens in mice represent a relevant model for allergic contact 
dermatitis. Following percutaneous penetration, the hapten 
covalently binds to host proteins thereby generating a neo-antigen 
that is eventually recognized by the immune system (102, 103). 
The emergence of CHS critically depends on the activation of 
hapten-specific naïve T cells in skin-draining LN during hapten 
sensitization, which then proliferate and differentiate into effector 
T cells that mediate a transient ear swelling reaction at the time of 
hapten challenge. In agreement with the LC paradigm, although 
haptens can passively drain to LN via afferent lymphatics, the 
induction of a productive T cell response hinges on the trans-
port of haptenized antigens by migratory skin DC to the T cell 
areas of the nodes. Therefore, when the first in vivo LC ablation 
mouse models were introduced, it came as a surprise that CHS 
was similar (46) or reduced, but not absent (44), after inducible 
depletion of LC in the skin prior to hapten sensitization (Table 2). 
These findings suggested that LC were not essential to induce the 
ear swelling reaction and that dermal DC contributed to T cell 
activation in CHS. Moreover, LC had no role in regulating the 
effector T cell response as was demonstrated by comparable ear 
swelling following diphtheria toxin treatment after sensitization 
but prior to hapten challenge (46, 104).
When the Langerin+ dermal DC subset was discovered in 
2007 (47–49), it became clear that these initial experiments 
had been performed in the absence of both Langerin+ skin DC 
TABLe 2 | Contact hypersensitivity reactions in mice with specific defects in skin dendritic cell subsetsa.







DT inducible cell depletion systems
Langerin-DTR (DT days −1 to −3) – – ↔ ↓ or ↔ (dependent on hapten 
conc.)
(44, 46, 47, 104, 105)
Langerin-DTR (DT days −7  
to −13)
– ↓ (30%) ↔ ↓ or ↔ (dependent on hapten 
conc.)
(47, 105)
Langerin-DTR BM → WT chimeras ↔ – ↔ ↔ (106)
hLangerin-DTR – ↔ ↔ ↑ (107)
Constitutive cell deficiency
hLangerin-DTA – ↔ ↔ ↑ (45)
LC/DC-specific TGF-βR1−/− – ↔ ↔ ↓ (75, 108)
LC/DC-specific p14−/− – ↔ ↔ ↓ (59)
Batf3−/− ↔ – ↔ ↔ (91)
a– indicates an absent cell population, ↓ indicates a reduction and ↔ means no change in cell number, functionality or CHS intensity, and ↑ indicates an increase in the CHS reaction.
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populations and not in the selective absence of epidermal LC 
as one had assumed [because all Langerin+ DC in the dermis 
were considered to be LC en route to local LN (46)]. However, 
in agreement with their continuous replenishment from blood-
borne precursors, it turned out that following injection of diph-
theria toxin the dermal Langerin+ DC recovered much faster, 
i.e., within 7–10 days, while the long-lived self-maintaining LC 
stayed away for a prolonged period of time, i.e., at least 2–4 weeks 
(44, 47, 105). Using timed diphtheria toxin treatments, this 
enabled researchers to induce CHS when both Langerin+ skin 
DC (administration of diphtheria toxin 1–3 days prior to hapten 
sensitization) or only LC (diphtheria toxin treatment 7–13 days 
before sensitization) were lacking. Alternatively, Langerin-DTR 
into wild-type bone marrow chimeras permitted the selective 
depletion of only Langerin+ dermal DC before the induction 
of CHS (106). From this comprehensive analysis by a number 
of different laboratories, it became clear that the intensity of 
the CHS reaction is directly correlated with the efficiency of T 
cell priming, as was suggested by inefficient antigen transport 
to draining LN in the absence of Langerin+ skin DC (104). 
Consequently, and in agreement with early dose–response 
studies (109), LC are required for efficient induction of CHS 
responses, in particular, at low hapten doses, while at higher 
hapten concentrations sufficient amounts of antigen can be 
picked up by dermal DC – both Langerin+ and negative – for 
effective elicitation of CHS in the absence of LC (37, 47, 105, 
106, 110, 111). Taken together, there is overwhelming evidence 
indicating functional redundancy of the different skin DC 
subsets in CHS (Table 2).
In contrast to these inducible Langerin-DTR knock-in mouse 
models, which harbor physiologic numbers of LC and Langerin+ 
dermal DC until the injection of diphtheria toxin, human (h)
Langerin-DTA BAC transgenic mice that constitutively lack LC 
throughout life mounted enhanced ear swelling responses (45). 
Although this observation suggested that LC may exert a down-
regulatory function in CHS, the great amount of data discussed 
above rather support compensatory roles of the different skin DC 
populations during the sensitization and elicitation of CHS (37, 
47, 105, 106, 110, 111). Apart from these reports, it is difficult to 
conceive how negative regulatory properties of LC could develop 
or be maintained in the highly inflammatory setting of a CHS 
sensitizing reaction (112). However, the reason for the discrep-
ancy between the inducible and the constitutive LC ablation 
models remains elusive. On the one hand, hLangerin-DTA mice 
may develop increased CHS as a result of some unknown failing 
peripheral tolerance mechanism in the lifelong absence of LC 
and therefore may respond differently during hapten sensitiza-
tion and/or may possess altered T cell properties (37, 111, 113). 
On the other hand, the Langerin+ dermal DC that return after 
the toxin treatment in Langerin-DTR mice may differ from the 
cells that originally developed during ontogeny (58), and which 
are left untouched in hLangerin-DTA mice, presumably due to 
differences in the transcriptional regulation of the mouse and 
human langerin promotors. Both of these hypothetical explana-
tions seem unlikely, however, because all transgenic mouse strains 
that constitutively lack LC (or Langerin+ dermal DC) as a result 
of varying genetic defects, i.e., independently of the diphtheria 
toxin/DTR system, and that have been tested in CHS mount 
similar or attenuated ear swelling reactions than LC-competent 
controls (Table  2) (75, 91, 101, 108). Instead, hLangerin-DTA 
mice may develop aggravated CHS due to changes in the homeo-
stasis of dermal DC populations, i.e., an increased number of 
CD103+ dermal DC (92), or due to unknown DNA sequences 
that have been introduced with the human langerin-containing 
BAC. Although speculative as well, the latter may be implied, 
because to date hLangerin-DTR mice generated with the same 
BAC construct are the only other mouse model that mount 
enhanced CHS responses, i.e., after acute diphtheria toxin-
mediated ablation of LC (107).
In conclusion, while LC clearly have regulatory potential that 
may have evolved to prevent inappropriate immune activation to 
keratinocyte-derived antigens or by commensal skin microbiota 
(see below), the vast majority of the available evidence indicates 
that LC promote the induction of CHS reactions, but are only 
essential at low hapten concentrations, and that dermal DC also 
contribute to CHS.
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FUNCTiONAL SPeCiALiZATiON OF 
CUTANeOUS DeNDRiTiC CeLLS iN 
iNFeCTiOUS SKiN DiSeASe AND 
HOMeOSTASiS TO COMMeNSAL 
MiCROBiOTA
One of the first observations questioning the LC paradigm was 
the finding that during cutaneous herpes simplex virus-1 (HSV-1) 
infections not epidermal LC, but instead CD8α+ LN-resident 
DC were responsible for T cell priming and induction of the 
anti-HSV-1 response (114). Notably, LC were still required to 
process and transport HSV-derived antigens to the LN, where 
they transferred their antigenic cargo to the CD8α+ LN DC for 
cross-presentation to naïve T cells (115). Another study using an 
HSV-2 infection model of the vagina also revealed that epithelial 
LC did not present viral antigens to LN T cells (116). In this case, 
submucosal CD8αneg migratory DC carried the viral peptides to 
the LN and induced the protective T helper (Th) type-1 response 
to HSV-2. A key question concerning these HSV infection mod-
els remains why LC played no direct role in antigen presentation 
and T cell activation. Was it merely because they were infected 
and killed by the cytopathic herpes viruses (117, 118); essentially 
leaving no other option for the apoptotic LC than being taken up 
and cross-presented to CD8+ T cells by LN-resident DC (119).
This hypothesis is supported in an apoptosis-inducing vac-
cinia virus infection model, in which cytotoxic T cell activation 
was similarly taken over by CD8α+ LN-resident DC, i.e., after 
uptake and cross-presentation of apoptotic skin-derived DC. On 
the other hand, in a cutaneous lentiviral infection model where 
LC/DC stay alive, migratory skin DC are perfectly capable to 
present antigen to T cells in the draining LN (120). Eventually, 
this concept was also confirmed for the HSV model, at least for 
Langerin+CD103+ dermal DC (121). In contrast to the primary 
infection via superficial skin scarification, during reactivation 
of the virus from its natural reservoir in the cutaneous nerves, 
HSV antigen presentation to CD8+ T cells occurred by both 
Langerin+CD103+ skin DC and CD8α+ LN DC. LC still played 
a minor role in direct antigen presentation, most likely due to 
higher sensitivity to this cytolytic virus than dermal DC. Although 
this concept that antigen-carrying skin DC, in particular LC, are 
taken up for cross-presentation by CD8α+ LN-resident DC can-
not be generalized (119), it was later found that Langerin+CD103+ 
dermal DC cross-present keratinocyte-derived antigens irrespec-
tive of the presence of epidermal LC (see below) (51). A compre-
hensive overview of the role of DC in primary HSV infections 
beyond these basic principles has been published recently (122).
LC were originally also considered to be critical for the induc-
tion of protective immunity in another infectious skin disease, 
namely cutaneous leishmaniasis, because they were shown to 
transport the parasites from the site of infection to skin-draining 
LN (123). This view was challenged when it was reported – at about 
the same time that the seminal HSV infection studies were pub-
lished (114, 116) – that LangerinnegCD8αneg presumably dermal 
DC, but not LC, act as principal antigen-presenting cells (APC) 
in experimental Leishmania major infection (124). Resistance to 
L. major infection and healing of the skin lesions both in mice 
and men critically depends on the efficient induction of a Th1/T 
cytotoxic (Tc) type-1 response (125, 126). Langerin-DTR mice in 
combination with timed diphtheria toxin treatments (see above) 
revealed that activation of L. major-specific CD8+ T cells is sig-
nificantly reduced during the early phase of the immune response 
following depletion of Langerin+ DC, without affecting the CD4+ 
T cell response and clearance of the infection (127). This dem-
onstrated that Langerinneg dermal DC were indeed essential for 
effective priming of CD4+ Th1 cells, whereas Langerin+ dermal 
DC were involved in early priming of CD8+ Tc1 cells.
Moreover, formation of CD4+ follicular helper (TFH)/B cell 
conjugates is crucial for B cell differentiation and class switch 
recombination to generate high-affinity antibodies for host protec-
tion following infection with L. major parasites (128). Recently, 
LC were shown to promote germinal center formation and thus 
antibody affinity maturation in response to Leishmania-derived 
cutaneous antigens (129), although these experiments used non-
physiologic high doses of parasites that might blur early events 
during infection. In a model of physiologic low-dose infection 
with L. major infectious-stage promastigotes (1,000 parasites), 
mice depleted of all Langerin+ DC developed smaller ear lesions, 
decreased parasite loads and a reduced number of CD4+Foxp3+ 
Treg cells, which was accompanied by increased production of 
interferon γ (IFNγ) (130). Of note, despite repeated administration 
of diphtheria toxin over a prolonged period of time (20 weeks) 
Langerin+ DC were efficiently depleted from the skin, confirming 
the absence of anti-diphtheria toxin neutralizing antibody forma-
tion as had previously been demonstrated (113, 131). Intriguingly, 
selective depletion of LC at the time of low-dose L. major inocu-
lation demonstrated that the absence of LC, and not Langerin+ 
dermal DC, was responsible for the reduced Treg cell immigration 
and the enhanced Th1 response, resulting in attenuated disease 
(130). Hence, LC act as negative regulators of the anti-Leishmania 
response in mice. This may be important to prevent complete 
eradication of the parasites from the host, which leads to the loss 
of T cell memory and susceptibility to reinfection (132, 133).
Candida albicans is a dimorphic fungus accountable for chronic 
cutaneous and systemic infections in immune-compromised 
hosts. On the stratum corneum of the skin, commensal C. albicans 
grows as budding yeast, while pathogenic C. albicans in the der-
mis and internal organs exists predominantly in its filamentous 
form, i.e., as pseudo-hyphae (134). This yeast-to-hyphae transi-
tion during epidermal invasion is required for both virulence 
and the generation of protective Th17 responses to cutaneous 
C. albicans (134, 135). On the other hand, systemic fungal 
immunity is achieved by innate immune mechanisms regulated 
by IL-17-mediated licensing of NK cells to promote the fungicidal 
activity of neutrophils (136).
Taking advantage of a superficial skin infection model that 
does not bypass the epidermis in combination with LC-deficient 
hLangerin-DTA mice, it was demonstrated that LC are essential 
for the induction of antigen-specific Th17, but not cytotoxic 
T lymphocyte (CTL) responses (137). Somewhat inconsistent, 
despite reduced IL-17 and similar IFNγ responses in the absence 
of LC, hLangerin-DTA mice mounted significantly increased 
DTH reactions after epicutaneous C. albicans infection, similar to 
the unique phenotype of these transgenic mice in CHS [(45) and 
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as discussed above]. However, using human Langerin-specific 
antibodies for targeted antigen delivery to LC in hLangerin-DTR 
mice (not treated with diphtheria toxin), LC were also found to 
be sufficient for inducing Th17 cell differentiation.
By contrast, Langerin+ dermal DC promoted antigen-specific 
Th1 and efficiently cross-presented fungal antigens to activate CTL 
responses. At the same time, Langerin+ dermal DC suppressed 
the ability of LC to drive the generation of Th17 cells (137). A 
follow-up study indicated that infection with C. albicans yeast 
but not pseudo-hyphae was capable of inducing Th17 responses 
through a mechanism that required Dectin-1 ligation on LC and, 
as a consequence, LC-derived IL-6 (138). In the dermis, absent 
Dectin-1 engagement by C. albicans pseudo-hyphae prevents 
Th17 induction by CD11b+ dermal DC. Moreover, Th17 cells 
were found to provide protection against secondary cutaneous 
infection whereas Th1 cells were protective against systemic 
reinfection (138). Together these elegant studies established that 
distinct and opposing Th cell responses are determined by a com-
bination of differences in C. albicans morphology and functional 
specialization of skin-resident DC subsets.
Beyond the functional specialization of skin DC subsets to 
deal with particular pathogens, there is accumulating evidence 
that the interactions between the resident skin microbiota and 
DC autonomously shape tissue homeostasis and local immunity 
(139). Skin tissue of mice housed under specific pathogen-free 
(SPF) conditions harbors Foxp3+ Treg as well as αβ+ and γδ+  
T cells with the potential to produce IFNγ and/or IL-17A, 
respectively. Microbial products from skin commensals tightly 
regulate this balance between Treg and effector T cells as was 
indicated by the increase in Treg and the reduction in IFNγ and 
IL-17A producing T cells in germfree mice lacking microbial 
products from their skin (139). Consequently, protective immu-
nity against L. major is severely impaired in germfree mice, as 
is disease-associated pathology. Intriguingly, colonization with 
the single skin commensal Staphylococcus epidermidis was 
sufficient to rescue cutaneous IL-17A production in germfree 
mice, which was dependent on IL-1 signaling in the skin. 
Monoassociation of germfree mice with S. epidermidis at the 
time of infection also restored immunity to L. major as well 
as pathology with increased necrosis (139). These results sug-
gest that defects in T cell function in the steady state or during 
inflammation can result from an impaired IL-1-mediated dialog 
with skin commensals.
Moreover, colonization of the skin of SPF mice that contained 
a diverse microbiota with S. epidermidis led to an accumulation 
of IL-17A+ CD8+ T cells in the epidermis that enhanced innate 
barrier immunity by upregulation of antimicrobial peptides and 
limited skin invasion of the pathogen C. albicans. In agreement 
with the unique role of CD103+ dermal DC in antigen cross-
presentation (see below), these Tc17 cells failed to develop in 
Batf3−/− and IRF8−/− (see Table  1), while the IL-17A secreting 
CD8+ T cells developed normally in constitutively LC-deficient 
hLangerin-DTA mice (92). Furthermore, CD11b+ dermal DC 
were required to promote the induction and/or maintenance of 
Tc17 cells through their capacity to produce IL-1 in response to 
S. epidermidis colonization of the skin. In conclusion, these find-
ings reveal that the skin immune system is highly dynamic and 
can be readily reshaped by the coordinated action of the different 
skin DC subsets upon encounter of defined commensals (92).
Hence, in agreement with the extended LC paradigm 
(Figure 1), LC exhibit a great degree of functional plasticity and 
become tolerogenic or immunogenic depending on the nature of 
the invading pathogen they encounter in the skin.
CROSS-PReSeNTATiON BY SKiN 
DeNDRiTiC CeLLS: QUeSTiON  
FiNALLY ANSweReD?
For developing immunotherapeutic approaches against cancer, 
one prerequisite is to understand how the various skin DC subsets 
induce CTL responses. There has been a long-standing debate 
on the ability of LC to cross-present exogenous antigen to CD8+ 
T cells (37). The start of this debate was the report that LC are 
dispensable for the induction of cytotoxic T cell responses against 
skin infection with herpes virus (see above) (114), which was later 
confirmed for vaccinia virus (140). Subsequent work clarified 
that cytopathic viruses induce apoptosis in LC rendering them 
sole transporters of antigen. As a consequence these cells are no 
longer capable of directly inducing T cell responses, however, 
LN-resident DC and other skin DC subsets, such as Langerin+ 
dermal DC, can step in and cross-present antigen to CD8+ T cells 
(115, 141, 142).
The debate was further fueled by studies on cross-presentation 
of self-antigen. For this approach, transgenic mice overexpress-
ing ovalbumin protein in an inducible or constitutive way under 
control of the keratinocyte-specific K5- or K14-promoter in the 
skin were employed (143–145). Now it was possible to examine 
cross-presentation of self-antigen by the various skin DC subsets 
in the steady state and inflammation. Early studies demonstrated 
that Langerin+ cells can cross-present ovalbumin to antigen-
specific CD8+ T cells (26, 146, 147). This cross-presentation abil-
ity was not necessarily restricted to Langerin+ dermal DC, since 
LC purified from trypsinized epidermis and migratory LC from 
epidermal explants also efficiently cross-presented ovalbumin to 
CD8+ T cells in vitro (144, 148). Chimeric mice in which antigen 
cross-presentation was restricted to LC proved that LC are able to 
cross-present self-antigen also in vivo. Interestingly, cross-pres-
entation by Langerin+ skin DC led to tolerance induction through 
deletion of antigen-specific CD8+ T cells (26). After the discovery 
of Langerin+ dermal DC, it came as a big surprise, when studies 
using K5-ovalbumin transgenic mice established that Langerin+ 
dermal DC are the sole cross-presenters of keratinocyte-derived 
antigen (51, 121). The localization of Langerin+ dermal DC 
adjacent to hair follicles where K5+ keratinocytes are present 
explained how this DC subset gains access to an epidermal 
antigen (49, 149). Moreover, in human skin keratinocyte-derived 
keratin bodies were found in the dermis (150). The discrepancy 
to the earlier studies, proving that LC can cross-present antigen, 
may be due to the low migratory capacity of LC in the steady 
state, which ensures that the LC network stays intact until inflam-
mation causes accelerated emigration of LC to LN (21, 43, 151). 
Indeed, the turnover of LC in the skin is much lower than that of 
dermal DC as demonstrated by BrdU incorporation assays (51). 
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The migration of all skin DC populations increases dramatically 
in an inflammatory setting, though with different kinetics, so that 
dermal DC arrive in LN much earlier than LC (46, 152). Hence, 
it would be interesting to investigate the cross-presentation of 
skin-derived antigen in an inflammatory setting at different time 
points after the onset of inflammation. Aside from this, most of 
the studies performed to date used transgenic mice overexpress-
ing the model antigen ovalbumin in keratinocytes. Because of the 
high-affinity T cell receptor binding and very strong responsive-
ness of ovalbumin-specific CD8+ T cells, these findings might not 
reflect what happens in real life (37). Thus, these studies need 
to be confirmed in a more physiological setting investigating the 
cross-presentation of genuine self-antigens in the skin.
For the development of immunotherapeutic strategies exploit-
ing skin DC, exogenous antigen needs to be delivered through 
the skin (see below). Studies on skin immunization added 
more issues to the controversy whether LC can cross-present 
exogenous antigen. First of all, LC can induce CTL when they 
are loaded with soluble ovalbumin in vitro and co-cultured with 
CD8+ T cells (148). Most importantly, topical application of oval-
bumin onto the skin by either epicutaneous immunization (153) 
or by dissolving micro-needles (154) confirmed that Langerin+ 
DC are involved in cross-priming of CD8+ T cells and that LC 
are superior to Langerin+ dermal DC, in particular, when the 
antigen is encapsulated in nanoparticles (154). In line with this, 
antibody-mediated targeting of the model antigen ovalbumin to 
Langerin+ cells by intradermal injection proved that both, LC and 
Langerin+ dermal DC, can cross-present antigen to CD8+ T cells 
in vivo (155).
Finally, to answer the question asked above, yes, both LC and 
Langerin+ dermal DC in the skin can cross-present exogenous 
antigen to CD8+ T cells in  vitro and in  vivo. We would like to 
emphasize that cross-presentation and cross-priming must not be 
equated. There is the very likely possibility that the various skin 
DC subsets induce different functional outcomes in CD8+ T cell 
differentiation as exemplified in a recent report. Despite initial 
CD8+ T cell proliferation induced by LC and Langerin+ dermal 
DC after loading them in situ with protein antigen (proving cross-
presentation), LC did not cross-prime T cells but rather induced 
cross-tolerance. By contrast, Langerin+ dermal DC promoted 
cytotoxicity, indicating that they indeed cross-primed the T cells 
(155). Thus, we need to better understand the differential contri-
butions of the various skin DC subsets in CD8+ T cell activation 
leading to either CTL differentiation or tolerance induction. 
This knowledge is indispensable for the future development of 
DC-based immunotherapy of cancer.
SKiN DeNDRiTiC CeLLS iN CANCeR
Novel immunotherapeutic strategies to vaccinate through the 
skin are a promising area of research for the future development of 
anti-cancer therapies. The rationale behind this approach comes 
from reports on the involvement of DC in tumor immunity and 
their outstanding potential in promoting T cell responses. The 
presence of DC has been reported in many different tumors, how-
ever, their specific role in tumor immunity is still incompletely 
understood (156, 157). Aside from this, tumors also strongly 
impair DC function and actively prevent efficient immunosur-
veillance by DC (158). With respect to cutaneous cancer, such 
as squamous cell carcinoma (SCC), basal cell carcinoma (BCC), 
and melanoma, several reports indicate that the numbers and 
function of skin DC are affected by tumor growth.
So far few studies attempted to analyze the specific role of skin 
DC present in cutaneous tumors. Non-melanoma skin cancer, 
such as SCC and BCC, are tumors of basal keratinocytes, making 
it very likely that LC are the first APC getting in contact with 
transformed cells. Two studies used patient samples from SCC 
to investigate LC and DC in regard to numbers, phenotype, and 
T cell stimulatory capacity. In the first study, the numbers of LC 
in the SCC tumor lesions were decreased as compared to healthy 
epidermis. Less myeloid cells, including dermal DC, were found 
around tumor nests than in normal skin. Tumor-associated 
myeloid DC were poor stimulators of allogeneic T cells despite 
displaying an activated phenotype (159, 160). The second study 
demonstrated that tumor-infiltrating LC are more activated and 
induced higher CD4+ and CD8+ allogeneic T cell proliferation 
as well as IFNγ production than LC from adjacent healthy skin 
(161). Thus, LC and myeloid DC found in human SCC samples 
display an activated phenotype, but only LC induce allogeneic T 
cell responses. Although suggestive, these studies do not allow 
any conclusion on the functional ability of these DC subsets to 
promote tumor immunity to non-melanoma skin cancer since 
tumor-specific T cell responses were not investigated. However, 
unhindered tumor growth despite the activation of LC/DC indi-
cates that the immunosuppressive milieu in SCC tumors, which 
contains high concentrations of TGF-β1 counteracts successful 
tumor immunity (159).
Another study used a murine model of chemically induced 
SCC to investigate the role of LC during tumor development 
(162). Chemical carcinogenesis was induced by application 
of the carcinogen 7,12-dimethylbenz(a)anthracene (DMBA) 
that causes Hras mutations, followed by the tumor-promoting 
agent 12-O-tetra-decanoyl-phorbol-13-acetate (TPA) leading to 
development of papilloma and subsequent SCC. The observation 
that hLangerin-DTA mice, lacking LC throughout their lifetime, 
are completely protected from tumor development is somehow 
surprising, but may be related to the intrinsically enhanced elici-
tation of adaptive immune responses, i.e., in CHS and DTH reac-
tions, in this as opposed to other LC-deficient mouse models (see 
above). However, the authors propose the interesting concept that 
LC mediate the metabolic conversion of DMBA to its mutagenic 
metabolite that in turn leads to DNA damage and carcinogenesis. 
They further suggest that compared to keratinocytes LC express 
higher levels of CYP1B1, an enzyme of the cytochrome P-450 
family responsible for the mutagenic metabolism of DMBA (162). 
How the metabolite is transferred from LC to keratinocytes to 
exert its DNA-damaging function was not investigated. Moreover, 
these data are difficult to reconcile with the fact that keratinocytes 
themselves express all required enzymes for DMBA metabolism 
(163, 164). In a follow-up paper, the authors demonstrated that 
LC exert pro-carcinogenic effects also independently of the 
enzyme CYP1B1 (165), possibly by aryl hydrocarbon receptor-
mediated transcription of other CYP enzymes that trigger DNA 
damage (166).
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In addition, LC played an important role in the progression 
of tumors by affecting the hyperproliferation of keratinocytes in 
the DMBA-induced SCC model (165) as well as in UVB-induced 
SCC (167), likely by augmenting IL-22 production by keratino-
cytes. Notably, this direct carcinogenic role of LC may be ampli-
fied by LC-driven immunosuppression, which is the induction 
of antigen-specific Treg cells upon UV radiation exposure (166, 
168). It will be interesting to compare the growth of chemically 
and UVB-induced SCC in the hLangerin-DTA mouse model 
(165, 167) to one of the inducible Langerin-DTR knock-in mice 
(44, 46), since the constitutive absence of LC in hLangerin-DTA 
mice may have a distinct effect on the development of the skin 
immune system (see above). Intriguingly, a recent report revealed 
an unaltered expression profile of cytochrome P-450 enzymes 
in the absence of LC and Langerin+ dermal DC upon DMBA 
application in Langerin-DTR mice (169).
Similar as in SCC and BCC, the role of the different skin 
DC in the immunosurveillance of melanoma is incompletely 
understood. Over 20 years ago first reports described decreased 
numbers of LC above invasive human melanoma (170, 171). In 
line with these findings, the presence of transplantable tumors 
lowered the number and impaired the migration of LC from 
murine skin (172). The types and relative proportions of tumor-
infiltrating DC in melanoma have not been determined so far, 
such that information on the functional potential of distinct 
skin DC subsets to control melanoma is lacking. For instance, in 
melanoma the accumulation of mature DC of unknown origin 
in draining LN metastases was associated with the expansion of 
antigen-specific cytotoxic T cells (173). A recent effort to identify 
the various myeloid cell types within a transplantable murine 
melanoma model demonstrated that the CD103+ DC subset, 
which most likely includes Langerin+ dermal DC, was superior 
over CD11b+CD103neg DC in cross-presenting tumor antigens 
(174). Future studies using multi-color flow cytometry including 
a comprehensive panel of markers to discriminate individual DC 
subsets (Figures 3 and 4) will be required to obtain a detailed 
picture on the involvement of distinct skin DC in tumor immu-
nity (175). This knowledge will form the basis for the design of 
novel and for the improvement of existing immunotherapies 
harnessing the potential of skin DC for the immunotherapy of 
cancer.
HARNeSSiNG SKiN DeNDRiTiC CeLLS  
AS TARGeTS FOR iMMUNOTHeRAPY  
OF CANCeR
From the time of the experiments of William Coley in the 
early 1900s immunotherapy of cancer was in the minds of 
immunologists (176), though it played a rather marginal role. 
Next to T cells, cytokines and antibodies, DC became promising 
targets for immunotherapy of cancer owing to the pioneering 
work by the late Ralph Steinman, who received the 2011 Nobel 
Prize in Physiology or Medicine for “his discovery of the DC 
and its role in adaptive immunity” (177). His ultimate goal 
was to harness the outstanding immunogenic properties of 
DC for immunotherapy and thereby “taking dendritic cells 
into medicine” (178). Since the first report of treatment of a 
B cell lymphoma with antigen-pulsed DC from blood (179), 
many clinical and basic research centers have been working 
to improve the efficacy of DC-based strategies to treat cancer 
patients. The first adoptive DC therapy for cancer (Provenge™, 
a tumor antigen-pulsed cell suspension containing DC) was 
approved by the FDA in 2010, and this constituted a milestone 
in the development of cellular therapies. A parallel development 
in cancer immunotherapy occurred over the past few years 
when the so-called “checkpoint inhibitors” were introduced 
into clinical practice. These antibodies against CTLA-4, PD-1, 
or PD-L1 (and presumably other inhibitory mediators in the 
future) switch off down-regulatory signaling pathways in 
T cells. They are therefore able to powerfully unleash anti-cancer 
immunity that exists in patients but is obviously insufficient or 
suppressed by various mechanisms (180). Clinical responses in 
patients are impressive, but so are side effects (autoimmunity), 
particularly with the anti-CTLA-4 antibodies. Still, these clini-
cal observations have earned this therapeutic approach the title 
of “Breakthrough of the Year” in 2013 by Science (181).
In spite of these encouraging developments targeting T cells, 
the potential of DC-based therapies remains high for several 
reasons. (i) Only a variable part of patients treated by checkpoint 
blockade responds to the treatment (180, 182, 183). (ii) Even 
though undesired autoimmunity can be clinically managed, it 
would be advantageous to avoid or minimize it from the begin-
ning. (iii) Most importantly, checkpoint blockade can only boost 
those cancer-specific T cells that are already preexisting in the 
patient. By contrast, DC therapy would be able to generate de novo 
immune responses (182, 183). Such responses would be desired 
against neo-antigens (“private mutations”) in patients’ tumors 
(182, 184). DC-induced T cell responses against such mutated 
tumor antigens would additionally lack autoimmune danger.
The ex vivo generation of DC for therapy is laborious, neverthe-
less, therapy with tumor antigen-pulsed autologous DC proved 
to be safe and effective, though not curative, in patients with 
solid tumors (185). The continuing importance of DC therapy 
is highlighted by recent publications, indicating persuasive ways 
of improving DC vaccines. For instance, DC were loaded with 
peptides derived from neo-antigens identified from the patient’s 
own tumor material, instead of the commonly used peptides 
from overexpressed self-antigens. This strategy augments T cell 
responses by broadening the antigenic diversity of the anti-
tumor response in the absence of autoimmunity (186). Another 
approach is the conditioning of the injection site with a potent 
recall antigen, such as tetanus toxoid, TLR ligands, or cytokines. 
The pretreatment of the skin site with antigen or danger signals 
improved the migration of adoptively transferred DC and boosted 
T cell responses in tumor-bearing mice (187–189). Moreover, 
the co-administration of tumor-binding allogeneic antibod-
ies enhanced the internalization of tumor antigens by DC and 
dramatically increased therapy outcome in murine tumor models 
(190). Furthermore, the choice of DC subset could enhance the 
efficacy of DC therapy as has been demonstrated for LC-like cells 
generated from CD34+ precursor cells that were able to overcome 
tolerance to differentiation antigens commonly overexpressed in 
cancer patients and used for vaccination (191).
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Yet another imaginative approach that has been pioneered 
many years ago in Ralph Steinman’s laboratory (192, 193) is the 
use of antibody-mediated antigen targeting constructs to specifi-
cally deliver antigenic peptides or proteins to DC in situ. The basic 
idea is to target the antigen of interest to endocytic receptors 
specific for DC (subsets) resident in the skin or lymphatic organs 
to enable them to efficiently incorporate antigen for presentation 
to T cells. This approach would be much less laborious than the ex 
vivo generation of DC from patients’ monocytes and their subse-
quent loading with tumor antigens. Intriguingly, antigen delivered 
without adjuvant can induce tolerance, whereas concomitant 
administration of TLR ligands and agonistic anti-CD40 antibody 
causes strong induction of CD4+ and CD8+ T cell responses (192, 
194). In addition, this approach allows delivering antigen into the 
various skin DC subsets by aiming at different lectin receptors 
(195, 196). The most interesting candidate receptors for these 
in  vivo antigen targeting approaches are C-type lectins, which 
are expressed by skin DC, e.g., DEC-205, Langerin, and Dectin-1 
(197–199). Specific delivery of the model antigen ovalbumin 
into Langerin+ cells proved that both LC and Langerin+ dermal 
DC can cross-present antigen to CD8+ T cells, however, only the 
dermal DC promoted the development of cytotoxicity while LC 
induced tolerance (155). Targeting antigens to DEC-205+ DC led 
to tumor control or even eradication in murine tumor models, 
albeit the relative roles of skin DC and LN-resident DC were 
not investigated in these studies (194, 200, 201). The chemokine 
receptor XCR1, which is preferentially expressed on Langerin+ 
dermal DC (52, 53) (Figure 3), is another promising target due 
to the fact that this DC subset excels in inducing cytotoxicity in 
CD8+ T cells (155). Immunization with the chemokine XCL1 
conjugated to ovalbumin protein intravenously or through skin 
pre-treated with a laser to form pores led to CD4+ and CD8+ T 
cell activation and inhibited the growth of transplanted tumors in 
mice (202, 203). First clinical trials have been initiated and so far 
demonstrated induction of some humoral and cellular immunity 
by targeting the tumor antigen NY-ESO-1 conjugated to DEC-
205 antibody into DC of patients with various solid tumors (204). 
These data demonstrate the proof-of-concept of the targeting 
approach in human cancer, but they also call for intense further 
study to substantially improve this strategy.
Immunization strategies through the skin are very attractive 
for their easiness of use and, ultimately, the possibility of self-
medication in case of topical treatment. Several approaches have 
been developed such as epicutaneous immunization, micro-nee-
dles, laserporation, or powder injection (205). The epicutaneous 
approach allows to topically apply antigens in protein and peptide 
form onto the skin (206). The disruption of the skin barrier 
and the addition of an adjuvant proved to be essential to elicit 
powerful cytotoxic T cell responses that inhibit tumor growth 
(153, 207, 208). The involvement of Langerin+ skin DC in CD8+ 
T cell responses was confirmed in experiments with Langerin-
DTR mice in a tumor setting. In line with findings in the CHS 
model (see above), the antigen dose of ovalbumin protein deter-
mined which skin DC subset presented the tumor antigen. The 
inhibition of tumor growth by epicutaneous immunization with 
low-dose antigen was completely abrogated in the Langerin-DTR 
mice depleted for Langerin+ DC, whereas application of a higher 
dose of antigen still partly inhibited tumor growth even in the 
absence of Langerin+ DC (153). This supports the notion of the 
high plasticity of skin DC subsets. The epicutaneous immuniza-
tion approach has already been clinically tested and proved to be 
promising for the treatment of cancer and infection (209, 210).
Another very elegant approach is the application of dissolving 
micro-needles that allow delivery of antigens right into the tissue 
where skin DC are located. This strategy has been successfully 
used to vaccinate against influenza (211) and to treat tumors, at 
least in murine models (154). The latter study demonstrated that 
LC can be superior to dermal DC in cross-presentation of antigen 
delivered with micro-needles into the skin. Interestingly, the 
nature of the antigen determined which skin DC subset induced 
CD8+ T cell proliferation, in that encapsulated antigen was prefer-
entially cross-presented by LC whereas soluble antigen required 
Langerin+ dermal DC for CD8+ T cell activation. The CD4+ T 
cell response was promoted by all skin DC subsets, however, LC 
dominated the induction of Th1 and Th17 responses (154).
For the future, it will be worthwhile to investigate the potential 
of the various cutaneous DC subsets in skin immunization and 
translate the findings from murine tumor models to the patient 
situation. Undoubtedly, skin DC are critically involved in survey-
ing the skin in order to prevent tumor growth and clearly fulfill 
an immunogenic role during vaccination against cancer. Yet their 
precise roles are still unclear and need to be clarified before we 
will arrive at urgently needed more effective DC-based treatment 
options for cancer.
HUMAN SKiN DeNDRiTiC CeLL SUBSeTS
The human and murine skin DC network seems to be highly 
conserved between the two species. While this justifies in vivo 
experiments in mice to gain mechanistic insight into the 
functional specialization of cutaneous DC subsets in regulating 
immunity and tolerance, we need to identify the human coun-
terparts of the murine DC subtypes in order to translate this 
knowledge to treating patients. In the recent years, human skin 
DC subsets were better defined and found to be homologous to 
murine DC (Figure 4) (212–214). In humans, the epidermis con-
tains LC expressing Langerin and high levels of CD1a, whereas in 
the dermis three subsets of dermal DC can be distinguished (37, 
215). The largest population is represented by the CD1c+CD1a+ 
dermal DC, which correspond to the murine CD11b+ dermal 
DC (216, 217). The smallest subset of DC in human dermis 
is characterized by high expression of CD141 and XCR1 and 
is homologous to the murine Langerin+CD103+ dermal DC, 
which also express XCR1 (214, 218). Very recently evidence for 
yet another small subset of (weakly) Langerin+CD1c+ dermal 
DC was presented, highlighting that similar to mice Langerin 
expression may not be strictly confined to LC in human skin 
(219). The CD14+ dermal DC are monocyte-derived cells that 
are transcriptionally aligned rather to monocytes/macrophages 
than to DC (216). A corresponding tissue-resident DC subset 
with the phenotype CD11b+Ly6C−CD64lo-hi has been described 
in murine dermis (35).
In regard to functional aspects, both human LC and CD1c+ 
dermal DC can polarize Th1 and Th2 responses (220), depending 
FiGURe 4 | Dendritic cell subsets in human skin. Scanning electron microscopy picture of a section through the skin depicting several layers of keratinocytes 
and the collagen meshwork of the dermis (38). Photograph by courtesy of Kristian Pfaller and Patrizia Stoitzner. Phenotypically distinct human skin-resident DC 
subsets are described by their most prominent markers. The color code represents the murine counterparts shown in Figure 3.
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on the cytokine milieu in the skin (221), and cross-present exog-
enous antigen to CD8+ T cells (215). However, the recently 
discovered CD141hi dermal DC excel in cross-priming of CD8+  
T cells comparable to murine Langerin+ dermal DC (214). There 
still exists some controversy in the field on the suitability of XCR1 
and CD141 as markers for cross-presenting DC since both mole-
cules can also be expressed by some CD1a+ and CD14+ dermal DC 
(218, 222, 223). Importantly, the methods used for the preparation 
of skin DC differ strongly between the many studies published. 
Notably, DC isolated from skin tissue by enzymatic digestion or 
derived from skin explant culture after emigration from the tissue 
(“crawl-outs”) represent immature and mature DC, respectively. 
This has major influence on their phenotype/function and the 
presence/absence of cell surface markers. One example is CD141, 
which is differently expressed on freshly isolated dermal DC and 
migratory dermal DC. While CD141 is upregulated on CD14+ 
dermal DC upon emigration from skin explants as compared to 
DC enzymatically isolated from skin, its expression on CD141high 
CD14neg dermal DC remains unaltered upon migration (214, 
223). Humoral immunity is mainly modulated by CD14+ dermal 
DC since they can activate the differentiation of TFH cells (220). 
Moreover, CD14+ dermal DC support memory T cell activation, 
most likely in situ in the skin, but they are poor stimulators of 
naïve T cells (216). During inflammation, several inflammatory 
DC subsets, e.g., inflammatory dendritic epidermal cells (IDEC), 
6-sulfoLacNAc+ (slan) DC, and TNF-α/iNOS-producing (Tip) 
DC, are recruited to the skin and have a strong impact on the 
course of inflammatory skin diseases such as psoriasis and atopic 
dermatitis (215, 224, 225).
Despite the high degree of homology between mouse and 
human skin DC, functional disparities do exist. Some examples 
are listed here: (i) For instance, with the help of IL-15 released 
into the immunological synapse, human LC cross-prime cyto-
toxic CD8+ T cell responses (226, 227). As a consequence human 
LC are able to break tolerance to self-antigens and stimulate 
cytotoxic T cell responses (191). So far hardly any information 
on the production of IL-15 by murine skin DC is available. 
(ii) CD70, a molecule involved in DC–T cell interaction and 
important for activation of CD8+ T cells and IFNγ production 
(228), is highly expressed by human LC (229, 230), whereas 
murine LC show very low levels of CD70 even after stimulation 
(155). These functional disparities between murine and human 
LC are supported by recently published gene transcription 
profiles of human skin DC subsets, indicating that human LC 
are more closely related to murine Langerin+ dermal DC than 
to murine LC (222). (iii) Another example for functional dif-
ferences stems from the fact that murine LC, despite initial 
cross-presentation and induction of CD8+ T cell proliferation 
(148), fail to stimulate cytotoxicity in CD8+ T cells and instead 
induce cross-tolerance (155). Notably, the TLR ligands used in 
the latter study specifically activate Langerin+ dermal DC (231), 
thus we need to evaluate the potential of LC in cross-priming 
with TLR ligands suitable for their activation. The knowledge 
on functional properties of the various murine and human skin 
DC subsets is of eminent importance when we envisage novel 
immunotherapeutic approaches that need first to be tested in 
preclinical murine studies before they can be translated into the 
clinics.
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